Position in DNLI
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$401,257
+$102,006 QoQ
Shares Held
15,601
+0.1% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
#163
of 290 holders
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Breakwater Capital Group holds $2,533,174 across 7 Biotechnology names. DNLI ranks #2 (15.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,992 | $989,486 | |
| 2 | DNLI |
Denali Therapeutics Inc.
This page
|
15,601 | $401,257 | |
| 3 | CYTK |
Cytokinetics Inc
|
3,941 | $335,733 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,007 | $303,137 | |
| 5 | CORT |
Corcept Therapeutics Inc
|
2,832 | $246,242 | |
| 6 | REPL |
Replimune Group, Inc.
|
19,900 | $220,293 | |
| 7 | RXRX |
Recursion Pharmaceuticals, Inc.
|
10,089 | $37,026 |
All Filings in DNLI
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $401,257 | 15,601 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $299,251 | 15,586 | Shares | Sole | 2026-04-20 | |
| 2025-12-31 | $270,202 | 16,366 | Shares | Sole | 2026-01-09 | |
| 2025-09-30 | $230,374 | 15,866 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $239,173 | 17,096 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $204,128 | 15,015 | Shares | Sole | 2025-04-10 | |
| 2024-09-30 | $222,611 | 7,642 | Shares | Sole | 2024-10-04 | |
| No filing history on record for this holder in this stock. | ||||||